South Korea-based contract development and manufacturing organisation Samsung Biologics has expanded its manufacturing footprint with the acquisition of a US biologics facility, a move relevant to construction-linked industrial supply chains and pharmaceutical manufacturing capacity.

Coverage from PR Newswire indicates the company completed its purchase of a manufacturing site in Rockville, Maryland from GSK, adding 60,000 litres of capacity and bringing total global capacity to 845,000 litres.

The site comprises two cGMP manufacturing plants supporting clinical and commercial biologics production, enabling multi-scale operations and strengthening regional supply for pharmaceutical and advanced manufacturing sectors.

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” said John Rim, president and ceo of Samsung Biologics. “The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family.”

He added that the facility would play a central role in supporting partners to deliver therapies globally while maintaining operational continuity and manufacturing standards across its network.

The company will continue supplying existing products to GSK under the agreement, while transitioning the site to serve broader contract manufacturing demand, supported by planned investments in capacity expansion and technology upgrades.

The acquisition establishes Samsung Biologics’ first manufacturing presence in the United States, complementing its existing operations in South Korea and commercial network across the US, Europe and Asia.

The development aligns with ongoing global demand for biologics manufacturing capacity, particularly as pharmaceutical pipelines expand and supply chain resilience remains a priority for industrial production.

Discover the full details of the acquisition in the complete article.